Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Conditions: Gastric; Colorectal Adenocarcinoma Interventions: Drug: tislelizumab Sponsors: China Medical University, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials